Alex Rodriguez Getty

Clinic records suggest Alex Rodriguez purchased HGH as recently as 2012; other players named

96 Comments

Over the weekend news broke that MLB and the Drug Enforcement Administration were investigating a clinic in Miami run by Anthony Bosch, a noted friend, adviser and consultant to many baseball players.  Bosch’s clinic has long been associated with so-called anti-aging therapies and he has long been associated with PEDs.  MLB reached out to the DEA because it does not have subpoena power and is interested in getting to the bottom of Bosch’s association with ballplayers.

Now a blockbuster report from the Miami New Times, which has been given patient records by an anonymous source, suggests that A-Rod and other ballplayers were, in fact, given HGH by Bosch. In A-Rod’s case as late as last year, long after he claimed that he had ceased using PEDs:

Yet there was his name, over and over again, logged as either “Alex Rodriguez,” “Alex Rod,” or his nickname at the clinic, “Cacique,” a pre-Columbian Caribbean chief. Rodriguez’s name appears 16 times throughout the records New Times reviewed.

Take, for instance, one patient list from Bosch’s 2009 personal notebook. It charts more than 50 clients and notes whether they received their drugs by delivery or in the office, how much they paid, and what they were taking.

There, at number seven on the list, is Alex Rodriguez. He paid $3,500, Bosch notes. Below that, he writes, “1.5/1.5 HGH (sports perf.) creams test., glut., MIC, supplement, sports perf. Diet.” HGH, of course, is banned in baseball, as are testosterone creams.

The New Times details multiple other records of banned substances, under either Rodriguez’s name or under his cousin Yuri Sucart. These include HGH, IGF-1, which stimulates muscle growth and is also banned and something called “troches,” which is a lozenge which releases testosterone.  But there is evidence of more recent use as well:

The mentions of Rodriguez begin in 2009 and continue all the way through last season. Take a page in another notebook, which is labeled “2012” and looks to have been written last spring. Under the heading “A-Rod/Cacique,” Bosch writes, “He is paid through April 30th. He will owe May 1 $4,000… I need to see him between April 13-19, deliver troches, pink cream, and… May meds. Has three weeks of Sub-Q (as of April).”

The New Times describes Sub-Q as a “mixture of HGH, IGF-1, and other drugs.”

Also mentioned in the records are Melky Cabrera, Yasmani Grandal and Bartolo Colon, all of whom have tested positive for PEDs in the past year.  One additional mention — a player never before linked with PEDs — is Nelson Cruz.  Gio Gonzalez is mentioned as well, but the records seem less definitive and may be connected to his father, who is quoted in the story.

The New Times attempted to get comment from all of the athletes named in the story. None responded.  Since the report was released, both Alex Rodriguez and Gio Gonzalez have issued statements.  Rodriguez’s statement, first reported by Joel Sherman of the New York Post:

“The news report about a purported relationship between Alex Rodriguez and Anthony Bosch are not true. Alex Rodriguez was not Mr. Bosch’s patient, he was never treated by him and he was never advised by him. The purported documents referenced in the story — at least as they relate to Alex Rodriguez — are not legitimate.”

Gonzalez’s statement:

“I’ve never used performance-enhancing drugs of any kind, and I never will. I’ve never met or spoken with Tony Bosch or used any substances provided by him. Anything said to the contrary is a lie.”

Major League Baseball has also issued a statement:

“We are always extremely disappointed to learn of potential links between players and the use of performance-enhancing substances.  These developments, however, provide evidence of the comprehensive nature of our anti-drug efforts.  Through our Department of Investigations, we have been actively involved in the issues in South Florida.  It is also important to note that three of the players allegedly involved have already been disciplined under the Joint Drug Program.

“The recommendations of the Mitchell Report have once again played a critical role in Major League Baseball’s ongoing efforts against performance-enhancing drugs.  MLB implemented all of the recommendations made by Senator Mitchell in 2007, several of which emphasized the significance of installing proactive investigative services.

“The establishment of our Department of Investigations has represented a critical advance in these comprehensive efforts.  In the years since its formation, DOI’s work has proven pivotal to bringing to light information regarding the use of performance-enhancing substances.  Furthermore, DOI has built strong working relationships with federal and local law enforcement authorities.  These relationships are crucial because only law enforcement officials have the capacity to reach those outside the game who are involved in the distribution of illegal performance-enhancing drugs.

“Vigilance remains the key toward protecting the integrity of our game.  We have the best and most stringent drug testing policy in professional sports, we continue to work with our doctors and trainers to learn what they are seeing day-to-day and we educate our players about the game’s unbending zero-tolerance approach.  We remain fully committed to following all leads and seeking the appropriate outcomes for all those who use, purchase and are involved in the distribution of banned substances, which have no place in our game.

“We are in the midst of an active investigation and are gathering and reviewing information.  We will refrain from further comment until this process is complete.”

This is a major, major story.  We have the east coast BALCO on our hands here.

Keep updating HardballTalk for the latest on this story and for our own unique analysis. Including Major League Baseball’s potential recourse against the named players and the likelihood that the Yankees could sue Alex Rodriguez to void his contract, which still has $114 million remaining.

Danny Espinosa reportedly skipped Nationals Winterfest because of Adam Eaton

WASHINGTON, DC - OCTOBER 13: Danny Espinosa #8 of the Washington Nationals celebrates after teammate Chris Heisey #14 (not pictured) hits a two run home run in the seventh inning against the Los Angeles Dodgers during game five of the National League Division Series at Nationals Park on October 13, 2016 in Washington, DC. (Photo by Rob Carr/Getty Images)
Getty Images
7 Comments

According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.

A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.

Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.

Espinosa will reach free agency after the 2017 season.

Nick Cafardo: Red Sox should deal Pomeranz, not Buchholz

BOSTON, MA - SEPTEMBER 18: Drew Pomeranz #31 of the Boston Red Sox pitches during the first inning against the New York Yankees at Fenway Park on September 18, 2016 in Boston, Massachusetts. The Red Sox won 5-4. (Photo by Rich Gagnon/Getty Images)
Getty Images
10 Comments

The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.

The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.

Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.

Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.